Advertisement

Topics

Adaptive Phage Therapeutics, Inc. Company Profile

14:42 EST 23rd January 2019 | BioPortfolio


News Articles [844 Associated News Articles listed on BioPortfolio]

Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pat...

CORRECTING and REPLACING Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage

Second paragraph, first sentence of release dated December 12, 2018, should read: ... Food and Drug Administration (instead of...Federal Drug Administration). The ...

CRISPR-Cas3 Platform Developer Locus Biosciences Acquires EpiBiome Phage Technology

Locus Biosciences, a developer of CRISPR-Cas3-engineered precision antibacterial products, has acquired EpiBiome’s high-throughput bacteriophage phage discovery platform for an undisclosed price, in...

Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

The post Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics appeared first on SynBioBeta.

Genentech, Adaptive Bio Join Forces on Personalized Cancer Drugs R&D

Genentech is paying Adaptive Biotechnologies $300 million up front in a new partnership focused on developing cancer immunotherapies personalized to individual patients. Seattle-based Adaptive has tec...

#jobs #lifescience Paramount Recruitment: Phage Display Scientist – Cambridge – 9 months FTC

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Paramount Recruitment: Phage Display Scientist – Cambridge – 9 mo...

Phage therapy draws renewed interest to combat drug-resistant microbes

(Children's National Health System) In the face of growing antibiotic resistance and few antibiotics in the development pipeline, phages are drawing renewed research interest as a potential silver bul...

Drug development innovations that work: Adaptive trial design

Adaptive trials can increase the potential of a drug launch by 13%. So why is this method still underutilized by the industry?

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [Kastle Therapeutics, LLC]

NA

Olopatadine hydrochloride [Somerset Therapeutics, LLC]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [Breathe Easy Therapeutics, Inc]

NA

Diclofenac sodium delayed release [Cambridge Therapeutics Technologies, LLC]

Diclofenac Sodium

Olopatadine hydrochloride [A-S Medication Solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [1084 Associated PubMed Articles listed on BioPortfolio]

The Promising Viral Threat to Bacterial Resistance: the Uncertain Patentability of Phage Therapeutics and the Necessity of Alternative Incentives.

Bacteriophages, or "phages," are a category of highly adept and adaptable viruses that can infect and kill bacteria. With concerns over the burgeoning antibiotic-resistance crisis looming in recent ye...

Host range and molecular characterization of a lytic Pradovirus-like Ralstonia phage RsoP1IDN isolated from Indonesia.

A lytic Ralstonia solanacearum-infecting phage designated Ralstonia phage RsoP1IDN was isolated from soil in Indonesia. The phage has a linear double-stranded DNA genome of 41,135 bp with 413-bp termi...

Phage defense mechanisms and their genomic and phenotypic implications in the fish pathogen Vibrio anguillarum.

Vibrio anguillarum is a marine bacterium that can cause vibriosis in many fish and shellfish species. Although phage therapy has been proposed as an alternative treatment, the defense mechanisms again...

Adjunct phage treatment enhances the effectiveness of low antibiotic concentration against Staphylococcus aureus biofilms in vitro.

Phage therapy is drawing more interest as antibiotic resistance becomes an ever more serious threat to public health. Bacterial biofilms represent a major obstacle in the fight against bacterial infec...

Bacteriophages on Dairy Foods.

This review focuses on the impact of bacteriophages on the manufacture of dairy foods. Firstly, the impact of phages of lactic acid bacteria in the dairy industry, where they are considered enemies, i...

Clinical Trials [708 Associated Clinical Trials listed on BioPortfolio]

Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage

This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects.

Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults

This study will examine the safety of ascending doses of AB-SA01 when topically applied to intact skin of healthy adults.

Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

This study aims to use a type of radiation (adaptive radiotherapy) to deliver curative-intent treatment to patients with non-small cell lung cancer, whose tumors would otherwise be too lar...

Adaptive Cardiac Resynchronization Therapy Study

The purpose of this study is to show that Adaptive CRT is at least as good at optimizing a patient's cardiac resynchronization therapy (CRT) as the current method of using an echocardiogra...

Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial

This study focuses on the validation of the Adaptation Index instrument as a measurement of adaptive behaviors used to reduce symptoms of FI and to describe the use of adaptive behaviors a...

Companies [1372 Associated Companies listed on BioPortfolio]

Adaptive Phage Therapeutics (APT)

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogeni...

Adaptive Phage Therapeutics, Inc.

Adaptive Phage Therapeutics, Inc.

Adaptive Corporation

Adaptive Corporation is a leading provider of Business Process Automation and Product Development technology and services. The company helps its customers become market leaders th...

Mercator Therapeutics, Inc.

Mercator Therapeutics is the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs. Mercator was founded to translat...

More Information about "Adaptive Phage Therapeutics, Inc." on BioPortfolio

We have published hundreds of Adaptive Phage Therapeutics, Inc. news stories on BioPortfolio along with dozens of Adaptive Phage Therapeutics, Inc. Clinical Trials and PubMed Articles about Adaptive Phage Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Adaptive Phage Therapeutics, Inc. Companies in our database. You can also find out about relevant Adaptive Phage Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record